Compare
Journey Medical Corp vs Nuvation Bio Inc. vs Fortress Biotech, Inc. vs Kura Oncology, Inc.
| Latest fiscal year | Journey Medical Corp DERM | Nuvation Bio Inc. NUVB | Fortress Biotech, Inc. FBIO | Kura Oncology, Inc. KURA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $61.24M | $62.90M | $63.26M | $67.48M |
| Revenue growth (YoY) | +11.1% | +699.0% | +9.7% | +25.2% |
| Gross margin | 65.8% (computed) | n/a | 66.9% (computed) | n/a |
| Operating margin | -13.3% | -338.7% | -111.0% | -449.9% |
| Net margin | -18.7% | -325.3% | 10.8% | -412.9% |
| Net income | -$11.43M | -$204.63M | $6.82M | -$278.67M |
| EPS (Diluted) | -$0.47 | -$0.60 | -$0.07 | -$3.18 |
| Operating cash flow | -$12.44M | -$173.43M | -$65.78M | -$64.06M |
| Free cash flow | n/a | n/a | n/a | -$70.70M |
| Cash & equivalents | $24.09M | $164.09M | $79.38M | $149.10M |
| Total assets | $94.59M | $594.82M | $185.55M | $738.36M |
| Total liabilities | $62.74M | $289.11M | $123.36M | $564.23M |
| Shareholders' equity | $31.85M | $305.72M | $49.87M | $174.13M |
| Return on year-end equity | -35.9% | -66.9% | 13.7% | -160.0% |
| Shares outstanding | n/a | 337.84M | 31.36M | 87.86M |
Revenue, most recent five fiscal years
| Fiscal year | Journey Medical Corp | Nuvation Bio Inc. | Fortress Biotech, Inc. | Kura Oncology, Inc. |
|---|---|---|---|---|
| Latest | $61.24M Ended 2025-12-31 | $62.90M Ended 2025-12-31 | $63.26M Ended 2025-12-31 | $67.48M Ended 2025-12-31 |
| 1 year earlier | $55.13M Ended 2024-12-31 | $7.87M Ended 2024-12-31 | $57.67M Ended 2024-12-31 | $53.88M Ended 2024-12-31 |
| 2 years earlier | $59.66M Ended 2023-12-31 | $0 Ended 2023-12-31 | $84.51M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $71.00M Ended 2022-12-31 | n/a | $75.74M Ended 2022-12-31 | n/a |
| 4 years earlier | $63.13M Ended 2021-12-31 | n/a | $68.79M Ended 2021-12-31 | n/a |